Product features interactive capabilites

Bristol-Myers Squibb chose Aegis’ Discoverant® software for process control during new product development.


Discoverant fits into Bristol-Myers Squibb’s strategy for implementing PAT and QbD, initiatives created by the FDA to encourage the use of innovative technology to help better understand the drug manufacturing process, according to Aegis.


“Aegis’ technology platform and application set provide a collaborative root cause analysis and decision-making environment to improve operational efficiencies and accelerate time to value by understanding the sources of variability and achieving overall process predictability,” explains Robert Di Scipio, Aegis president and CEO. “Discoverant provides users with interactive access to all types of process development and manufacturing data that is integrated with powerful analysis, trending, and reporting capabilities.”

Previous articleLoss of Cilia Linked to Cancer
Next articleGenmab Reclaims Antibody License from Merck